Peptides Are Penicillin

Every so often, medicine stumbles onto a class of therapies so powerful that they reset expectations--not just for what we can treat, but for how society thinks about disease itself. Penicillin did this in the 20th century. Peptides are doing it now.

The uncomfortable truth is that penicillin was both one of the greatest inventions in human history and one of the worst businesses ever created. Peptides appear to be walking the same path: scientifically miraculous, societally transformative, and structurally destined for commoditization.

That tension--between public good and private incentive--is the story. And for investors, the question isn't whether peptides will change medicine. It's where in the value chain the money will actually stick.

The Penicillin Precedent

Penicillin didn't just cure infections. It ended an era. Before antibiotics, minor cuts could kill you. Pneumonia was a coin toss. Surgery was a gamble against invisible enemies. Alexander Fleming discovered penicillin's antibacterial properties in 1928, but it took Howard Florey and Ernst Chain at Oxford to develop it into a usable drug in the early 1940s. By the time the Allies deployed it during World War II, it was saving thousands of lives. Fleming, Florey, and Chain shared the 1945 Nobel Prize in Physiology or Medicine.

Here's the part most people forget: Florey and Chain deliberately chose not to patent penicillin. Florey believed it would be unethical to restrict access to a life-saving medicine. The British scientists handed their discovery to the world. The U.S. government coordinated mass production. Prices collapsed. Competition exploded. Penicillin became infrastructure--essential, invisible, and unmonetizable at scale.

The Peptide Revolution

Peptides are taking a different route to the same destination.

At a biological level, peptides are elegant. They're short chains of amino acids--the same building blocks your body already uses to signal, regulate, repair, and defend itself. Hormones, neurotransmitters, immune signals: many of them are peptides. We've been running on peptide software since multicellular life began.

What's changed is our ability to design, stabilize, and deliver them deliberately.

In the last decade, peptides have quietly demonstrated capabilities that traditional small-molecule drugs struggle to match. They bind precisely. They act cleanly. They modulate systems rather than bludgeon them. They can tell cells to grow, stop, repair, calm down, or self-destruct with uncanny specificity.

From a clinical standpoint, this is magic. From a business standpoint, the picture is more complicated.

Unlike penicillin, peptides are being patented aggressively. Novo Nordisk's semaglutide--the molecule behind Ozempic and Wegovy--has patent protection extending into the 2030s and potentially the 2040s through patent term extensions and thickets. These are not unprotected molecules. Right now, they're printing money.

But the protection is temporary, and the pressure is relentless. During shortages, compounding pharmacies have exploited regulatory loopholes to produce copycat versions at a fraction of branded prices. When patents eventually expire, biosimilars and generics will flood the market. The core molecules will become commodities.

The Infrastructure Trap

This is the pattern that keeps repeating in medicine, and it's the part investors routinely miss.

The closer a therapy gets to the body's native biology, the faster it collapses toward infrastructure. Breakthroughs that rewrite medical baselines don't sustain monopoly profits; they dissolve them. Once a drug moves from marvel to expectation, society reorganizes around access, scale, and reliability--not margins.

Penicillin didn't fail as a business because it was mishandled. It failed because it worked too well. The same dynamic shows up again and again: vaccines, insulin, anesthesia, sanitation, antibiotics. Each began as a miracle, attracted capital and competition, and ended as something civilization refuses to live without. At that point, pricing power vanishes.

Peptides are on that trajectory. The molecules themselves will not be where durable value accumulates. The value will live above them: in manufacturing precision, delivery systems, diagnostics, distribution, and combinations that integrate peptides into broader therapeutic stacks. That's where defensibility survives after exclusivity expires.

History suggests a pattern worth paying attention to. The most transformative medical technologies don't enrich monopolists forever. They enrich civilization.

Penicillin didn't make many people rich in the long run. It made almost everyone else alive.

Peptides feel like they're aiming for the same outcome.